ClinicalTrials.gov
public full text
Public Domain
Using FAPI PET/MRI to Evaluate Prostate Cancer
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer#894090
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers#1245066
- PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment#871250
- Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma#812150
- Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients#1409148
Record · ID 1409155
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive